CoChat

Comparison of the clinical features and clinical course of antimitochondrial antibody‐positive and ‐negative primary biliary cirrhosis

The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.

Abstract

Reports from North America and Northern Europe have suggested that antimitochondrial antibody (AMA) negative primary biliary cirrhosis (PBC) is a distinct chronic cholestatic liver disease with high prevalence of serum non-organ-specific autoantibodies other than AMA. To evaluate if such a peculiar serum immunoreactivity is associated with clinically relevant characteristics, we reviewed our experience with 297 Italian patients who have had a clinical and histological diagnosis of PBC and were regularly followed-up at our Center from June 1974 to June 1994. AMA-negative and AMA-positive patients were compared in terms of biochemical and clinical features, and clinical outcome of the disease. At presentation, 30 of 297 patients (10%) tested negative for AMA by indirect immunofluorescence. Six of them tested positive for antimitochondrial M2 antibodies (AMA-M2) by immunoblotting analysis, therefore, diagnosis of AMA-negative PBC was made in 24 patients (8%). At the initial visit, AMA-negative and AMA-positive patients were similar in terms of biochemical and clinical features. Antinuclear and anti-smooth-muscle antibodies (ANA and ASMA) were more frequently positive in the AMA-negative patients (71% vs. 31%, and 37% vs. 9%; both P = .0002). Incidence of complications of cirrhosis and development of liver failure resulting in death or referral for liver transplantation did not differ significantly between the two populations. In conclusion, data from this historical cohort study suggest that the distinct serological features of AMA-negative PBC are not associated with substantial differences in the clinical spectrum or course of the disease.

Overview

Integrity signals

Registry

Crossref · 10.1002/hep.510250507

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 19 references

Cited by

See all 294

Metadata

Authors
Invernizzi, P., Crosignani, A., Battezzati, P. M., Covini, G., De Valle, G., Larghi, A., Zuin, M., & Podda, M.
Affiliations
Ospedale San Paolo (IT)
Venue
Hepatology
Published
1997-05
Volume
25
Issue
5
Pages
1090-1095
ISSN
0270-9139 (ISSN-L)
OpenAlex
W1994218082
Cited by
293
References
18
Citations by year
2026: 1 · 2025: 4 · 2024: 4 · 2023: 5 · 2022: 5 · 2021: 7 · 2020: 7 · 2019: 4 · 2018: 7 · 2017: 8 · 2016: 5 · 2015: 10 · 2014: 11 · 2013: 6 · 2012: 18
FWCI
8.07
Type
journal article
Language
en
Open access
closed
Licence
doi.wiley.com/10.1002/tdm_license_1.1 (tdm, 6697 d)
Locations
  • Hepatology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
  • Health Sciences › Medicine › Surgery › Pediatric Hepatobiliary Diseases and Treatments
  • Health Sciences › Medicine › Rheumatology › IgG4-Related and Inflammatory Diseases
Keywords
primary biliary cirrhosis, antimitochondrial antibodies, antinuclear antibodies, anti-smooth muscle antibodies, non-organ-specific autoantibodies, clinical course, cirrhosis complications, liver failure, liver transplantation, cholestatic liver disease
MeSH terms
Adult, Aged, Autoantibodies, Female, Humans, Liver Cirrhosis, Biliary, Male, Middle Aged, Mitochondria, Prognosis, Autoimmunity

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Comparison of the clinical features and clinical course of antimitochondrial antibody‐positive and ‐negative primary biliary cirrhosis. https://app.cochat.ai/papers/10.1002/hep.510250507
The paper
Invernizzi, P., Crosignani, A., Battezzati, P. M., Covini, G., De Valle, G., Larghi, A., Zuin, M., & Podda, M. (1997). Comparison of the clinical features and clinical course of antimitochondrial antibody‐positive and ‐negative primary biliary cirrhosis. Hepatology. https://doi.org/10.1002/hep.510250507

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.